OCUPHIRE PHARMA
Ocuphire Pharma is a clinical-stage biopharmaceutical company focuses on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. It is currently focused on providing a novel once-daily eye drop treatment option, Nyxol, to treat multiple front-of-the-eye disorders, including night vision disturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia. Nyxol eye drops are an investigational 505(b)(2) drug candidate in late-stage cl... inical development with over a decade of safety and efficacy data from Phase 1 and 2 trials. Part of their strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and the back of the eyes and to seek strategic partners for global commercialization. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.
OCUPHIRE PHARMA
Social Links:
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2018-02-01
Address:
Farmington Hills, Michigan, United States
Country:
United States
Website Url:
http://www.ocuphire.com
Total Employee:
1+
Status:
Active
Contact:
(248) 681-9815
Email Addresses:
[email protected]
Total Funding:
24.56 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Apple Mobile Web Clips Icon ReCAPTCHA Cloudflare Cloudflare Network Error Logging Cloudflare SSL ReCAPTCHA V2 CloudFront
Similar Organizations
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-06-17 | Rexahn Pharmaceuticals | Rexahn Pharmaceuticals acquired by Ocuphire Pharma | N/A |
Investors List
Altium Capital
Altium Capital investment in Post-IPO Equity - Ocuphire Pharma
Lincoln Park Capital Fund
Lincoln Park Capital Fund investment in Post-IPO Equity - Ocuphire Pharma
Ayrton Capital
Ayrton Capital investment in Post-IPO Equity - Ocuphire Pharma
District 2 Capital
District 2 Capital investment in Post-IPO Equity - Ocuphire Pharma
National Eye Institute
National Eye Institute investment in Grant - Ocuphire Pharma
Biosciences Research and Commercialization Center (BRCC)
Biosciences Research and Commercialization Center (BRCC) investment in Seed Round - Ocuphire Pharma
Blue Water Angels
Blue Water Angels investment in Seed Round - Ocuphire Pharma
Michigan Angel Fund
Michigan Angel Fund investment in Seed Round - Ocuphire Pharma
First Capital Fund
First Capital Fund investment in Seed Round - Ocuphire Pharma
BELLE Capital
BELLE Capital investment in Seed Round - Ocuphire Pharma
Official Site Inspections
http://www.ocuphire.com Semrush global rank: 2.23 M Semrush visits lastest month: 8.64 K
- Host name: 104.21.25.98
- IP address: 104.21.25.98
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Ocuphire Pharma"
Opus Genetics - Home
Preserving vision. Targeting mutations in genes causing inherited retinal diseases. Opus Genetics’ focus is on developing and advancing treatments to address mutations in genes that cause loss of vision, including …See details»
Ocuphire Pharma - Crunchbase Company Profile & Funding
Ocuphire Pharma is a clinical-stage biopharmaceutical company focuses on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. It is …See details»
Ocuphire Pharma - Overview, News & Similar companies - ZoomInfo
Nov 27, 2023 Who is Ocuphire Pharma. Ocuphire is a publicly traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and …See details»
Ocuphire Pharma - LinkedIn
Ocuphire Pharma | 4,551 followers on LinkedIn. Restoring Vision and Clarity | We are a late-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for ...See details»
Ocuphire Pharma Company Profile - Office Locations, Competitors …
Oct 29, 2024 Ocuphire Pharma has 5 employees at their 1 location and $19.05 m in annual revenue in FY 2023. See insights on Ocuphire Pharma including office locations, competitors, …See details»
Ocuphire Pharma acquires Opus Genetics - modernretina.com
Oct 22, 2024 In connection with the acquisition, Ocuphire issued 5.2 million shares of its common stock and 14.1 thousand shares of its convertible preferred stock to existing …See details»
Investor Relations :: Ocuphire Pharma, Inc. (OCUP)
Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy . Nov 2, 2023. View All News. Upcoming Events. AAO 2023 . Nov 3 – Nov 6, 2023 . View All Events. Latest Financial …See details»
Ocuphire Pharma Announces Acquisition of Opus Genetics
Oct 22, 2024 In connection with the acquisition, Ocuphire issued 5.2 million shares of its common stock and 14.1 thousand shares of its convertible preferred stock to existing …See details»
Ocuphire Pharma Announces Appointment of George Magrath, …
Nov 1, 2023 Dr. Magrath Brings Proven Executive Leadership, Medical and Clinical Expertise in Ophthalmic Drug DevelopmentFARMINGTON HILLS, Mich., Nov. 01, 2023 (GLOBE …See details»
Ocuphire Pharma Completes Transactions and Begins Trading
Nov 6, 2020 Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Contacts: …See details»
Ocuphire Pharma Announces Appointment of George Magrath, …
Nov 1, 2023 Dr. Magrath Brings Proven Executive Leadership, Medical and Clinical Expertise in Ophthalmic Drug Development. FARMINGTON HILLS, Mich., Nov. 01, 2023 (GLOBE …See details»
Ocuphire Pharma Completes Transactions and Begins ... - Yahoo …
Nov 6, 2020 Ocuphire’s second product candidate, APX3330, is a twice-a-day oral tablet, designed to target multiple disease pathways that contribute to the pathology of diabetic …See details»
Ocuphire to transform into gene therapy biotech via Opus buyout
Oct 23, 2024 As part of the deal, Ocuphire is offloading a clinical-stage candidate in the form of APX3330, an oral small-molecule inhibitor of Ref-1 for the treatment of non-proliferative …See details»
Ocuphire Pharma Strengthens Leadership Team with Key …
FARMINGTON HILLS, Mich., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic biopharmaceutical company …See details»
FDA gives its blessing to Ocuphire Pharma’s special protocol …
Jan 4, 2024 Ocuphire Pharma Inc announced it has received agreement from the FDA under a Special Protocol Assessment (SPA) for the clinical trial protocol and planned statistical …See details»
Ocuphire Pharma Announces Presentation at Ophthalmology …
Nov 30, 2023 Ocuphire has a partnership with Viatris, Inc. to develop and commercialize phentolamine ophthalmic solution 0.75%. Phentolamine is a non-selective alpha-1 and alpha-2 …See details»
Oculos Partner Ocuphire Pharma Announces Completion of the …
Sep 5, 2019 Ocuphire also initiated MIRA-1 in the summer and has already enrolled 26 subjects to date (representing 80% completion) at 4 U.S. sites. The objectives of this randomized, cross …See details»
Ocuphire Announces Enrollment of First Patients in Second Phase …
Nov 23, 2021 Ocuphire is collaborating closely on the Nyxol programs with a leading clinical research organization, Oculos Development Services (subsidiary of iuvo BioScience), which …See details»
Ocuphire Pharma Strengthens Leadership Team with Key …
Feb 14, 2024 Ocuphire also has a partnership with Viatris, Inc. to develop and commercialize phentolamine ophthalmic solution 0.75%. Phentolamine is a non-selective alpha-1 and alpha-2 …See details»
Ocuphire Announces Upcoming Clinical ... - Ocuphire Pharma, Inc.
Ocuphire previously completed the first Phase 3 registration trial in RM (NCT04620213) and Phase 2 trial in presbyopia (NCT04675151). As part of its strategy, Ocuphire will continue to …See details»